Effect of rifampin on the pharmacokinetics, safety and tolerability of navitoclax (ABT-263), a dual inhibitor of Bcl-2 and Bcl-XL , in patients with cancer. [electronic resource]
Producer: 20150626Description: 680-4 p. digitalISSN:- 1365-2710
- Aged
- Aged, 80 and over
- Aniline Compounds -- adverse effects
- Antineoplastic Agents -- adverse effects
- Area Under Curve
- Cytochrome P-450 CYP3A -- biosynthesis
- Cytochrome P-450 CYP3A Inducers -- pharmacology
- Drug Interactions
- Female
- Half-Life
- Humans
- Male
- Middle Aged
- Neoplasms -- drug therapy
- Proto-Oncogene Proteins c-bcl-2 -- antagonists & inhibitors
- Rifampin -- pharmacology
- Sulfonamides -- adverse effects
- bcl-X Protein -- antagonists & inhibitors
No physical items for this record
Publication Type: Controlled Clinical Trial; Journal Article
There are no comments on this title.
Log in to your account to post a comment.